Abstract：
Women go through several predictable conditions and symptoms during menopause that are caused by age, changes in sex hormone levels, and other factors. Conventional menopause hormone therapy has raised serious concerns about the increased risks of cancers, blood clots, depression, etc. Selective estrogen receptor modulators (SERMs) that can be both agonists and antagonists of estrogen receptors in a tissue-specific manner are being developed to reduce the health concerns associated with menopause hormone therapy. Here, we have searched the Chinese national traditional Chinese medicine (TCM) patent database to identify potential SERM-like compounds with reduced health risks. TCM has been widely used for treating complex symptoms associated with menopause syndrome and thus can be a particularly rich source for pharmaceutical alternatives with SERM properties. After extensive literature review and molecular simulation, we conclude that protopanaxatriol, paeoniflorin, astragalin, catalpol, and hyperoside among others may be particularly promising as SERM-like compounds in treating the menopausal syndrome. Compounds in TCM hold promise in yielding comparable outcomes to hormone therapy but with reduced associated risks, thus presenting promising avenues for their clinical applications.
摘要：
女性在绝经期间经历了几种可预测的疾病和症状，这是由年龄引起的，性激素水平的变化,和其他因素。传统的更年期激素治疗引起了人们对癌症风险增加的严重担忧，血凝块,抑郁症,等。选择性雌激素受体调节剂（SERM）可以以组织特异性方式成为雌激素受体的激动剂和拮抗剂，以减少与更年期激素治疗相关的健康问题。这里,我们检索了中国国家中药(TCM)专利数据库,以鉴定具有降低健康风险的潜在SERM样化合物.中药已广泛用于治疗与更年期综合征相关的复杂症状，因此可以成为具有SERM特性的药物替代品的特别丰富的来源。经过广泛的文献回顾和分子模拟，我们得出的结论是原参三醇，芍药苷,黄芪,catalpol,和金丝桃苷等作为SERM样化合物在治疗更年期综合征中可能特别有前途。中药中的化合物有望产生与激素治疗相当的结果，但相关风险降低。从而为其临床应用提供了有希望的途径。
